CF-Carvacrol

CF-Carvacrol is an orally active lipid-lowering agent synthesized by merging the pharmacophores of Carvacrol (HY-N0711) and Clofibric acid (HY-B1415) . CF-Carvacrol has a good affinity for PPAR-α. CF-Carvacrol has significant hypolipidemic activity and may exert antioxidant and anti-inflammatory activity by activating the Nrf2/HO-1 signaling pathway to reduce liver injury. CF-Carvacrol can be used for the study of CF-induced liver damage[1].

Product Specifications

UNSPSC

12352005

Target

Interleukin Related; Keap1-Nrf2; PPAR

Related Pathways

Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

CC(C1=CC(OC(C(C)(OC2=CC=C(C=C2)Cl)C)=O)=C(C=C1)C)C

Molecular Formula

C20H23ClO3

Molecular Weight

346.85

References & Citations

[1]Shi X, et al. Optimization of clofibrate by carvacrol results in a new hypolipidemic compound with low hepatic injury. Bioorg Med Chem Lett. 2025 May 1;120:130116./